Lindbrook Capital’s Vanda Pharmaceuticals VNDA Stock Holding History

Lindbrook Capital’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-73	Closed	-$412	–	2915
2024 Q2	$412	Buy	+73	New	+$377	﹤0.01%	2665
2023 Q3	–	Sell	-673	Closed	-$4.43K	–	2835
2023 Q2	$4.43K	Buy	673 +561	+501%	+$3.6K	﹤0.01%	1865
2023 Q1	$760	Sell	112 -438	-80%	-$3.08K	﹤0.01%	2511
2022 Q4	$4.07K	Sell	550 -96	-15%	-$935	﹤0.01%	1924
2022 Q3	$6K	Sell	646 -718	-53%	-$7.58K	﹤0.01%	1609
2022 Q2	$15K	Buy	1,364 +687	+101%	+$7.12K	﹤0.01%	1109
2022 Q1	$8K	Buy	677 +31	+5%	+$408	﹤0.01%	1407
2021 Q4	$10K	Hold	646	–	–	﹤0.01%	1287
2021 Q3	$11K	Hold	646	–	–	﹤0.01%	975
2021 Q2	$14K	Hold	646	–	–	﹤0.01%	918
2021 Q1	$10K	Hold	646	–	–	﹤0.01%	1036
2020 Q4	$8K	Hold	646	–	–	﹤0.01%	1016
2020 Q3	$6K	Buy	646 +96	+17%	+$1.03K	﹤0.01%	1064
2020 Q2	$6K	Hold	550	–	–	﹤0.01%	1041
2020 Q1	$6K	Buy	+550	New	+$6.82K	﹤0.01%	949

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Lindbrook Capital's VNDA Position: Q3 2024 in Review

Lindbrook Capital sold out of Vanda Pharmaceuticals (VNDA) in Q3 2024, closing a stake of 73 shares — an estimated $412 sold.

Lindbrook Capital first reported a position in VNDA in Q1 2020 and held it in 15 quarters. The position peaked at $15K in Q2 2022. 152 funds tracked by Wall St. Rank hold VNDA as of Q3 2024.

Lindbrook Capital reported no remaining Vanda Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Lindbrook Capital sold 73 Vanda Pharmaceuticals shares in Q3 2024, an estimated $412.
Lindbrook Capital first reported a position in Vanda Pharmaceuticals in Q1 2020 and held it in 15 quarters.
Lindbrook Capital's Vanda Pharmaceuticals position peaked at $15K in Q2 2022.
152 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2024.

Based on Lindbrook Capital's 13F filing for Q3 2024, filed 1 Nov 2024.